|Day Low/High||114.54 / 118.63|
|52 Wk Low/High||53.06 / 123.99|
Citron analyst sees 'indestructible moat' around genetic-testing company's business.
Jim Cramer talks about what investors need to do ahead of an expected rate cut and amid earnings and trade upheaval.
NEW YORK, July 29, 2019 /PRNewswire/ -- WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the Board of Directors of Genomic Health, Inc.
Cancer diagnostics company Exact Sciences will acquire healthcare company Genomic Health for about $2.8 billion.
U.S. stock futures are mixed as Wall Street prepares for a likely quarter-point rate cut from the Federal Reserve; Beyond Meat reports earnings on Monday; Pfizer will combine its off-patent drugs business with Mylan; Exact Sciences reportedly is in negotiations to buy Genomic Health.
- Estimated Cologuard® market share increased to 5.7 percent during the second quarter
Joins two of the strongest brands in cancer diagnostics, Cologuard® and Oncotype DX®, providing a strong platform for continued growth
Cancer diagnostics company Exact Sciences is in advanced talks to acquire Genomic Health for about $2.8 billion to strengthen its cancer-testing offerings, according to Bloomberg.
Hundreds of open positions offer opportunity to join growing company
MADISON, Wis., July 9, 2019 /PRNewswire/ -- Exact Sciences Corp.
Company's total lab processing capacity expected to reach 7 million by end of year
A roundup of Jim Cramer's thoughts on stocks of interest to Mad Money viewers.
By going after friendly trading partners and big tech Trump is forcing Wall Street to re-calibrate and lower valuations, Jim Cramer says.
MADISON, Wis., May 31, 2019 /PRNewswire/ -- Exact Sciences Corp.
Early data on pancreatic cancer detection presented at Digestive Disease Week® 2019
Researchers to Present Real-World Findings at Digestive Disease Week® 2019
Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in EXACT Sciences Corp. , where a total volume of 10,929 contracts has been traded thus far today, a contract volume which is representative of approximately 1.1 million underlying shares (given that every 1 contract represents 100 underlying shares).
MADISON, Wis., May 1, 2019 /PRNewswire/ -- Exact Sciences Corp.
- Estimated Cologuard market share increased to 4.6 percent during the first quarter
Former Health and Human Services Secretary brings government and health care expertise to company working to detect cancer earlier
Shares of Exact Sciences has been on the upswing, but the stock price of the cancer screening test firm may be vulnerable.
Jim Cramer's watching six stocks to determine when the selling will end.
MADISON, Wis., March 5, 2019 /PRNewswire/ -- Exact Sciences Corporation (NASDAQ: EXAS) (the "Company") today announced an underwritten public offering of $600 million aggregate principal amount of convertible senior notes due 2027 (the "Notes") pursuant...
MADISON, Wis., March 1, 2019 /PRNewswire/ -- Exact Sciences Corp.
Exact Sciences Announces Milestone Ahead of Cologuard Classic, National Colorectal Cancer Awareness Month
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.